Introduction
Chronic myelogenous leukemia (CML) is a malignant disease of the hematopoietic stem cell characterized by the presence of the Philadelphia chromosome (Ph) (Nowell and Hungerford, 1960) and the formation of the BCR/ABL fusion gene (Rowley, 1973) , encoding the p210 BCR/ABL oncoprotein. Clinically, CML is characterized by the premature circulation of a massively expanded immature myeloid progenitor and precursor pool in the blood. At the cellular level, CML is characterized by an increased proliferation, increased resistance to apoptosis and alterations in adhesion properties of leukemic progenitors. This review will discuss studies by others and our group over the last 10 years that evaluated mechanisms underlying abnormal trafficking and expansion of malignant progenitors in chronic myelogenous leukemia due to abnormal progenitor/microenvironment interactions in CML as a result of the oncoprotein. We will also discuss what is known to date regarding the molecular mechanisms underlying abnormal integrin function in CML.
Abnormal progenitor/microenvironment interactions in CML
Chronic myelogenous leukemia (CML) is characterized clinically by a massive expansion of immature progenitors and precursors that leave the bone marrow (BM) microenvironment prematurely. We have worked for the last 5 -10 years on the hypothesis that the abnormal expansion of malignant CML progenitors and their growth advantages over coexisting normal (NL) progenitors may be related to their lack of responsiveness to normal negative regulatory influences from the BM microenvironment. Gordon et al. (1989) showed that CML progenitors fail to adhere to BM stroma. We subsequently demonstrated that in contrast to NL primitive and committed progenitors, primitive and committed progenitors from CML BM fail to adhere to NL stromal layers, and to fibronectin (FN) and its proteolytic fragments, but do adhere to collagen type IV and laminin, extracellular matrix (ECM) components of basement membranes . NL progenitors adhere to stroma through a variety of cell surface adhesion receptors, including a4b1 integrin receptors, which bind to vascular cell adhesion molecule (VCAM) and the CS-1 region in the COOH-terminal heparin-binding domain of FN, and a5b1 integrin receptors, which bind to the RGDcontaining cell-binding domain of FN. In addition, a4b1 integrins and the glycosaminoglycans (GAGs) form of the CD44 receptor may cooperate to establish adhesion of NL committed progenitors to FN. Levels of the a4b1 and a5b1 integrin, and CD44 receptors are similar on CML BM progenitors as on NL progenitors suggesting that the function of these receptors is impaired in CML. In addition, a fraction of CML progenitors expresses a2b1 and a6b1 integrin receptors known to interact with laminin and collagens, whereas these receptors are absent from NL progenitors. These observations indicate that the premature release of CML progenitors into the circulation may be caused by loss of adhesive interactions with stroma and/or FN and acquisition of adhesive interactions with basement membrane components (Figure 1 ).
Other investigators have also shown abnormalities in the adhesive behavior of p210 BCR/ABL containing cells. Most studies were done using BCR/ABL containing cell lines. Bazzoni et al. (1996) showed that BCL/ABLtransfected GM-CSF or IL-3 dependent human (MO7e) and mouse (32D, Baf/3) hematopoietic cell lines adhere better to FN than mock-transfected cells. This effect was due to enhanced function of the VLA-5 integrin receptors and not to increased surface expression. Kramer et al. (1999) showed that expression of p21 BCR-ABL in 32D cells upregulates levels of a5b1 integrins, and induces adhesion to FN. Recently, Wertheim et al. (2002) confirmed that p210 BCR-ABL mediates increased adhesion of 32D cells to FN, but as was reported by Bazzoni et al. (1996) that changes in adhesion are independent of change in a5b1 and a4b1 integrins expression (Wertheim et al., 2002) . Furthermore, they found that the increased adhesion was independent of p210 BCR-ABL tyrosine kinase activity. Bazzoni et al. (1996) also evaluated the adhesion of CML CD34 + cells to FN and found that hematopoietic progenitors cells from CML patients have increased ability to adhere to FN than NL progenitors.
Combined, these studies provide a somewhat confusing picture regarding the ability of CML cells to adhere to FN. Several possible explanations may exist for the observed differences between the various studies. First, the majority of studies described above used hematopoietic cell lines, some of mouse and some of human origin, and some of the myeloid and some of the lymphoid lineage, in which BCR/ABL was introduced. Whether effects of BCR/ABL are different depending on the host cell is not known. A second explanation is that culture conditions and test conditions used in the different studies differed. Specifically the presence or absence of cytokines, and the type of cytokines used prior and during the adhesion assay differed. As integrins signaling is influenced by cytokines through an inside-out signaling mechanism, these differences in test conditions may affect the result of the studies. Finally, differences in duration of the adhesion assay may influence results, as Bazzoni et al. (1996) showed that CML cells adhere normally to FN for short periods (530 min), but are hypermotile and much more likely to come off the plate than normal cells. Therefore testing adhesion after 30 min may suggest normal or even increased adhesion, whereas extension of the adhesion assay to 1 -2 h may suggest decreased adhesion.
We and others have also reported that direct contact between NL progenitors and stroma is important for regulation of progenitor growth (Cashman et al., 1985; Verfaillie, 1992) . We demonstrated that proliferation of NL CFC is significantly inhibited when NL progenitors are cultured in contact with BM stroma or FN, suggesting that integrin-dependent adhesion inhibits NL progenitor proliferation (Hurley et al., 1995) . This was confirmed by experiments in which integrins were engaged by blocking monoclonal antibodies and secondary antibodies to induce capping of integrins (see below). In contrast to NL progenitors, CML progenitors proliferate continuously even when in contact with BM stroma (Eaves et al., 1986; Gordon et al., 1987; Verfaillie et al., 1992) . We hypothesized that the decreased integrin-mediated adhesion of CML progenitors to stroma and FN due to either functional or structural abnormalities in the b1 integrin may underlie not only the abnormal trafficking but also the increased proliferation of malignant CML progenitors. Consistent with this notion, incubation with the b1 Figure 1 Integrin-dependent signaling pathways. Following engagement of integrins, focal contacts are assembled that allow colocalization of a number of signaling molecules. Cytoskeletal rearrangement is required for the phosphorylation of the focal adhesion kinase Fak/Pyk-2 which binds directly to the intracellular domain of the b1 integrin. Following tyrosine phosphorylation, Fak/Pyk-2 serves to assemble secondary signaling molecules such as paxillin, p130 CAS , CRKL, PI3-K and Grb-2. In CML, p210 BCR-ABL causes phosphorylation and/or association with intracellular signaling molecules including CRKL, paxillin, Cbl, Grb-2 and PI3-K Abnormal integrin function in CML S Salesse and CM Verfaillie integrin activating antibody, 8A2, restored adhesion of CML progenitors and the CML leukemic cell line, K562, to FN through b1 integrins (Lundell et al., 1996) . In addition, CML CD34 + cells as well as K562 cells pre-treated with 8A2 prior to culture on FN inhibited their proliferation, without affecting cell differentiation, necrosis or apoptosis. These studies thus suggested that unresponsiveness of CML progenitors to negative regulatory influences from the BM microenvironment might be caused by inability to signal via b1-integrins. Moreover, 8A2 induced adhesion of CML progenitors to the GAG binding fragments of FN, indicating that activation of b1-integrins on CML progenitors also restores cooperation between b1-integrins and CD44 (Lundell et al., 1997) . The fact that decreased b1-integrin function may also affect the function of CD44, suggest that both may contribute to the abnormal circulation and expansion of malignant progenitors in CML.
Interferon-alpha (IFN-a) has been used for the last decade to treat patients with Ph + CML who are not candidates for allogeneic stem cell transplantation. It induces durable and complete cytogenetic responses in 10 -20% of IFN-a-treated patients, and increases duration of chronic phase and survival compared with conventional chemotherapy. The mechanisms by which IFN-a restores normal hematopoiesis in CML are not clear. We hypothesized that IFN-a may act by correcting the defective adhesion of CML progenitors to marrow stroma, which may in turn results in restoration of normal microenvironmental regulation of CML progenitor proliferation. Treatment of CML progenitors with IFN-a indeed induces a significant dose-dependent increase in the adhesion of primitive (LTC-IC) and committed (CFC) CML progenitors to NL stroma, which could be inhibited by blocking antibodies directed against a4, a5 and b1 integrins (Bhatia et al., 1994) . This suggested that IFN-a induces normalization of progenitor-stroma interactions in CML. Consistent with the premise that defective integrin-based interactions in CML are due to abnormal function -not expression -of a4b1 and a5b1 integrin receptors, integrin expression levels were unchanged after IFN-a treatment of CML CD34 + cells. As IFN-a may also affect adhesion of CML progenitors through indirect effects on the BM microenvironment, we examined the effect of IFN-a treatment of BM stroma on the subsequent adhesion of CML progenitors (Bhatia et al., 1995) . CML CFC and LTC-IC adhered significantly better to IFN-a pretreated stroma as compared with untreated stroma via a4b1 and a5b1 integrin adhesion receptors, suggesting that IFN-a-treatment of stroma also restores b1-integrin-mediated adhesion mechanisms in CML. Interestingly, this effect was due, at least in part, to IFN-a-induced increased stromal production of the chemokine, macrophage inflammatory protein-1a (MIP-1a), which itself upregulates integrin-dependent adhesion of CML progenitors to stroma.
We also examined the effects of IFN-a-induced restoration of CML progenitor adhesion on CML progenitor proliferation (Bhatia et al., 1996) . Proliferation of IFN-a-treated CML CFC was significantly inhibited following contact with stroma and FN, or following antibody-induced crosslinking of a4, a5 or b1 integrin receptors.
Whether direct or indirect restoration of adhesion via integrins is important in IFN-a-mediated remissions is currently not known. It is interesting to note that loss of the interferon consensus sequence binding protein (ICSBP), a transcription factor of the interferon (IFN) regulatory factor (IRF) family, leads to the development of CML-like syndrome in mice (Holtschke et al., 1996) . Recent studies have shown that ICSBP plays a role in adhesion, as elimination of ICSBP is associated with significantly reduced levels adhesion of colony-forming cells from ICSBP 7/7 BM to FN, as well as mature monocytes. As ICSBP regulates expression of the signal phosphoprotein, disabled-2 (Dab2) (Rosenbauer et al., 2002) , known to be important in cell adhesion and spreading, upregulation of Dab2 by IFN-a may be involved in the restoration of adhesion of hematopoietic cells in CML progenitors, a thesis that could be tested.
p210
BCR/ABL is directly responsible for defect in adhesion and adhesion-mediated regulation of proliferation
We demonstrated a direct role of p210 BCR-ABL in abnormal adhesion and adhesion-mediated regulation of proliferation of CML progenitors, by decreasing BCR-ABL expression with BCR-ABL breakpointspecific antisense oligodeoxynucleotides (AS-ODNs), and inhibiting p21 BCR-ABL kinase activity with protein tyrosine kinase (PTK) inhibitors . Incubation of primary CML CD34
+ cells with BCR-ABL breakpoint-specific AS-ODNs specifically and significantly reduced BCR-ABL mRNA and p210 BCR-ABL levels that resulted in restoration of integrin-mediated adhesion of CML CFC to stroma and a4b1 and a5b1 integrin binding fragments of FN, and inhibition of CML CFC proliferation after contact with stroma and FN or after antibody-mediated integrin stimulation . In addition, inhibition of p21 BCR-ABL kinase activity with Tyrphostin AG957, a PTK inhibitor that inhibits p210 BCR-ABL kinase activity, significantly increased CML CFC adhesion to stroma and a4b1 and a5b1 integrin binding fragments of FN . Although AG957 did not alter CML CFC proliferation by itself, treatment of CML CD34 + cells with AG957 prior to culture on FN significantly inhibited CFC proliferation. Another PTK inhibitor, Tyrphostin AG555, which does not have anti-p210 BCR-ABL kinase activity, did not affect CML CFC adhesion or proliferation, and neither AG957 nor AG555 affected normal CFC adhesion or proliferation. In addition, AG957 reduced tyrosine phosphorylation of several proteins, such as paxillin, Crk1, Cbl and the p85 subunit of the phosphinositol-3 (PI-3) kinase. These studies therefore strongly suggest that the Wertheim et al. (2002) recently showed for the 32D cell line transfected with a tyrosine kinase defective BCR/ABL cDNA. Whether differences in target cell (mouse cell lines vs primary human CD34 + cells) plays a role in these discrepancies is not known (Figure 2) .
To further prove that p210 BCR-ABL is responsible for the defects described above, we developed a primary human hematopoietic progenitor cell model for CML by transduction of BCR/ABL cDNA in normal CD34 + cells from umbilical cord blood (UCB) (Zhao et al., 2001) . UCB CD34 + cells were transduced with a murine oncoretroviral vector encoding the BCR/ABL cDNA upstream from an internal ribosomal entry site (IRES) and the enhanced green fluorescence protein (eGFP) cDNA, and selected by FACS for eGFP. As is seen in primary CML, there was significant excess in production of myeloid progenitors and precursors in BCR/ABL transduced CD34 + cells compared with mock-transduced cells, demonstrating an increased differentiation to the myeloid lineage. BCR-ABL in CML.
Molecular mechanisms underlying abnormal integrin function in CML
Interaction between integrins and the cytoskeleton plays a critical role in modulating integrin function both by affecting receptor conformation and ligand binding affinity as well as by modulating receptor mobility and clustering (O'Toole et al., 1994; Schwartz et al., 1995) . b1 integrin receptors associate directly and Figure 2 Regulation of G1 progression by p27 following growth factor effects or engagement of integrins. Members of the Cip/Kip family negatively regulate the activity of the cyclin-dependent kinase (cdk)-cyclin complexes that control progression through the G 1 /S phase of the cell cycle. Binding of p27 kip-1 to cyclin E-cdk2 prevents cells from entering the S phase. Engagement of b1 integrins regulates proliferation of normal CD34 + cells by up-regulating p27 kip-1 protein levels, with concomitant inhibition of cdk2 kinase activity. Growth factors override b1 integrin-mediated proliferation inhibition of normal hematopoietic cells by preventing up-regulation of p27 kip protein level and suppression of cdk2 kinase activity after integrin engagement
Abnormal integrin function in CML S Salesse and CM Verfaillie indirectly via their cytoplasmic tail with several cytoskeletal proteins including a-actinin, talin, vinculin, and tensin, to form multimolecular complexes known as focal adhesion (Burridge et al., 1988; Clark and Brugge, 1995; Miyamoto et al., 1995) . These interactions result in linkage of the extracellular matrix with F-actin fibers and lead to rearrangement of the actin cytoskeleton. In addition, signal transduction proteins such as Crkl, paxillin, and kinases such as the focal adhesion kinase, Fak or the related Pyk-2, and the phosphoinositol-3 kinase (PI-3 kinase), are recruited to focal adhesion complexes leading to activation of downstream signaling pathways (Guinebault et al., 1995; Salgia et al., 1996a) . We have started to evaluate whether abnormalities in b1 integrin-cytoskeletal interactions were present in primary CML progenitors and contribute to defective integrin function. In NL CD34 + cells, antibodymediated cross-linking of b1 integrin leads to redistribution of integrins into caps, resulting from an active process requiring receptor-cytoskeleton interactions and F-actin reorganization (Hurley et al., 1997) . We found that a4b1 and a5b1 integrin capping is significantly impaired in CML CD34 + cells, indicating that b1 integrin-cytoskeletal interactions required for normal receptor mobility are abnormal in CML (Bhatia et al., 1999) . We further demonstrated that this was caused by enhanced cytoskeletal binding of integrin receptors in CML cells. Treatment with IFN-a or PTK inhibitors partially reversed defective integrin-cytoskeletal interaction mediated integrin capping in CML progenitors. This study suggests that p210 BCR-ABL induces abnormal association of integrin receptors with the cytoskeleton and restricts receptors mobility.
Numerous studies analysed the signaling pathways involved in altered CML progenitors adhesion and demonstrated that interactions between p210 BCR-ABL and cytoskeletal elements important for b1 integrin signaling may be responsible for abnormal integrin function. Indeed, it was demonstrated that the localization of p210 BCR-ABL mainly in the cytoplasm compared with p160 ABL , (McWhirter and Wang, 1991 ) and the oligomerization of p210 BCR/ABL which activates the COOH-terminus actin binding domain (Van Etten et al., 1994) , cause enhanced binding to the actin cytoskeleton, and contributes to the transforming properties of BCR/ABL . Binding of p210 BCR-ABL to F-actin may alter the cytoskeleton directly. Alternatively binding of p210 BCR/ABL to the actin cytoskeleton result in colocalization of p210 BCR-ABL tyrosine kinase with cytoskeletal proteins involved in signaling through b1 integrins such as paxillin, talin, vinculin, focal adhesion kinase (Fak/Pyk-2), and CRKL that become substrates for phosphorylation (Gotoh et al., 1995; Oda et al., 1994; Salgia et al., 1995a,b) . The adaptor molecule, CRKL, which physically associates with a number of cytoskeletal proteins, has been implicated in regulating adhesion, is the main substrate for p210 BCR/ABL tyrosine kinase (Sattler and Salgia, 1998) . In BCR/ABL-transformed cell, CRKL was reported to constitutively associate with several focal adhesion proteins, including paxillin, establishing a link between p210 BCR/ABL and paxillin (Salgia et al., 1995c) . In addition, p130
CAS was found to be phosphorylated and associated with CRKL in BCR/ABL-expressing cell (Salgia et al., 1996b) . In normal cells, p130
CAS associate with paxillin, FAK and the focal adhesion protein tensin. However, in BCR/ ABL-transformed cells, the interaction between p130 CAS and tensin was disrupted while the association of p130 CAS with paxillin and FAK was unaffected. These studies suggest that p210 BCR/ABL may alter the function of p130 CAS by causing its phosphorylation, leading to constitutive association of p130 CAS with CRKL and disruption of its interaction with tensin. Furthermore, in p210 BCR/ABL -expressing cells, CRKL and the product of the proto-oncogene CBL are constitutively phosphorylated and form a permanent complex with p210 BCR/ABL , independent of integrin activation (Salgia et al., 1996c; Sattler et al., 2002) . This constitutive p210 BCR/ABL -mediated complex with proteins involved in integrin signaling may either constitutively transduce signals which are normally regulated by either integrin or growth factor receptor activation, and be responsible for the altered adhesion and mobility of CML cells. In addition, constitutive activation and phosphorylation of many of the focal adhesion proteins in CML, may render them unavailable for integrin mediated signaling, leading to decreased adhesion of CML progenitors.
We also tested mechanisms underlying defective integrin-mediated regulation of progenitor proliferation in CML. Members of the Cip/Kip family negatively regulate the activity of the cyclin-dependent kinase (cdk)-cyclin complexes that control progression through the G 1 /S phase of the cell cycle (Lloyd et al., 1999; Shiohara et al., 1997) . Binding of p27 kip-1 to cyclin E-cdk2 prevents cells from entering the S phase, and binding to cyclin A-cdk2 prevents passage through the S phase (Polyak et al., 1994) . Engagement of b1 integrins regulates proliferation of normal CD34 + cells by up-regulating p27 kip-1 protein levels, with concomitant inhibition of cdk2 kinase activity (Jiang et al., 2000a) . IL-3 and SCF, two hematopoietic mitogens, override b1 integrin-mediated proliferation inhibition of normal hematopoietic cells. IL-3 and SCF prevent up-regulation of p27 kip protein level and suppression of cdk2 kinase activity after integrin engagement. Several studies have shown that IL-3 and SCF activate signal pathways that are similar to those activated by p210 BCR-ABL (Carpino et al., 1997; Matulonis et al., 1993) . However, in contrast to what we observed with NL CD34 + cell treated with IL3 or SCF, p27 kip levels were significantly higher in primary CML CD34 + cells than in NL CD34 + cells, independent of cell adhesion (Jiang et al., 2000b) . p27 kip mRNA levels were similar in CML and NL CD34 + cells and remained unchanged after adhesion, suggesting posttranscriptional regulation. Elevated p27 kip levels in CML were not associated with increased binding of p27 kip to cdk2 and decreased of cdk2 kinase activity. In CML, p27 kip Abnormal integrin function in CML S Salesse and CM Verfaillie was relocated in the cell cytoplasm where it cannot interact with cdk2 that is located almost exclusively in the nucleus, suggesting that functional inactivation of p27 kip in CML is in part responsible for abnormal integrin-mediated growth regulation of CML CD34 + cells.
Loss of p27 kip expression was reported to contribute to oncogenesis and tumor progression and correlate with poor prognosis in human tumors. This finding was originally made in breast and colorectal carcinomas (Loda et al., 1997) , and has since been confirmed for a wide variety of human tumors (Catzavelos et al., 1997) . Interestingly, there is no proof that the p27 kip gene is mutated or deleted in human tumors, and low p27 kip protein expression is the result from regulation at the posttranscriptional level, in large part by increased proteasome-mediated degradation rather than altered gene expression. In CML, Gesbert et al. (2000) and Jonuleit et al. (2000) reported that BCR/ ABL directly promotes cell cycle entry by decreasing the level of p27 kip in IL-3 dependent BAF/3 and MO7e cell line, which was not the result of transcriptional regulation. Downregulation of p27
Kip could be directly attributed to the p210 BCR-ABL tyrosine kinase activity as treatment with the Abl tyrosine kinase inhibitor, STI571, resulted in increased p27 kip expression. p27 kip protein downregulation in BCR/ABL-expressing cells was likely to be due to a proteasome-dependent degradation, regulated by PI3K and AKT. Differences between this report and studies done by our group where elevated levels of p27 kip were seen in primary CML cells may be due to the use of growth factordependent murine and human cell lines vs CML and NL CD34 + cells.
Of note a recent study by Sugiyama et al. (2001) showed that p27 kip can be translocated into the cytoplasm via binding to the adaptor Grb2. As Grb2 plays an important role in BCR/ABL mediated activation of the Ras pathway, and hence the development of the myeloproliferative state in CML, studies are ongoing in the laboratory to further evaluate the relation between p27 kip and Grb2 in BCR/ABL + hematopoietic cells.
Conclusion and future directions
The studies described here review studies showing that abnormal expansion and trafficking of malignant progenitors in CML may at least in part be related to impaired integrin-mediated adhesion and growth regulation in CML primary progenitors. Ongoing studies are aimed at identifying the molecular mechanisms underlying the abnormal adhesion and proliferation of CML CD34 + cells. Preliminary studies showed in particular, that defects in Pyk2, PI3-K and Cdc42 pathways may be responsible for the defective adhesion and migration of CML CD34 + cells, and suggest a role of Grb2 in the functional inactivation of p27 kip in CML. Furthermore, the primary hematopoietic cell model for CML developed in our laboratory should prove to be a useful tool to study p210 BCR-ABL -mediated molecular mechanisms leading to the clinical features of CML.
